ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In comparison, GZD824, which was also identified as a BCR‐ABL inhibitor originally, has shown to be well‐tolerated while effectively inhibiting tumour growth in CML patients in Phase I/II clinical trials [19, 20, 21].